Resveratrol in Cancer Patients: From Bench to Bedside
Massimiliano Berretta(University of Messina), Nicola Maurea(Cancer Institute (WIA)), Alessia Bignucolo(University of Messina), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Di Francia(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Manuela Ceccarelli(Università degli Studi di Enna Kore), Rosario Vincenzo Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Comello(Centro di Riferimento Oncologico)
Cited by 105
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Epithelial-mesenchymal transition in prostate cancer: an overview
|Oncotarget|2017|177
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac Dysfunction
|European Journal of Heart Failure|2014|92